Bosutinib - an effective and safe treatment option in the management of chronic myeloid leukemia

被引：3
|
作者：
Ercaliskan, Abdulkadir [1 ]
Eskazan, Ahmet Emre [1 ]
机构：
[1] Istanbul Univ Cerrahpasa, Cerrahpasa Fac Med, Div Hematol, Dept Internal Med, TR-34303 Istanbul, Turkey
来源：
FUTURE ONCOLOGY | 2020年 / 16卷 / 03期
关键词：
adverse event; bosutinib; chronic myeloid leukemia; comorbidity; imatinib; tyrosine kinase inhibitor; KINASE INHIBITOR TKI; IMATINIB; DASATINIB; DISCONTINUATION; NILOTINIB; THERAPY; CML;
D O I：
10.2217/fon-2020-0006
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：4425 / 4428
页数：4
相关论文
共 50 条
  • [1] Bosutinib for the treatment of chronic myeloid leukemia
    Doan, Vi
    Wang, Alice
    Prescott, Hillary
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2015, 72 (06) : 439 - 447
  • [2] Phase 2 study of bosutinib in Japanese patients with newly diagnosed chronic phase chronic myeloid leukemia
    Hino, Masayuki
    Matsumura, Itaru
    Fujisawa, Shin
    Ishizawa, Kenichi
    Ono, Takaaki
    Sakaida, Emiko
    Sekiguchi, Naohiro
    Tanetsugu, Yusuke
    Fukuhara, Kei
    Ohkura, Masayuki
    Koide, Yuichiro
    Takahashi, Naoto
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2020, 112 (01) : 24 - 32
  • [3] Practical considerations in the management of patients treated with bosutinib for chronic myeloid leukemia
    Lipton, Jeffrey H.
    Bruemmendorf, Tim H.
    Sweet, Kendra
    Apperley, Jane F.
    Cortes, Jorge E.
    ANNALS OF HEMATOLOGY, 2024, 103 (09) : 3429 - 3442
  • [4] Bosutinib - related pleural effusion in patients with chronic myeloid leukemia
    Yuzbasioglu, Mebrure Burcak
    Eskazan, Ahmet Emre
    EXPERT OPINION ON DRUG SAFETY, 2021, 20 (04) : 379 - 381
  • [5] The role of bosutinib in the treatment of chronic myeloid leukemia
    Gambacorti-Passerini, Carlo
    le Coutre, Philipp
    Piazza, Rocco
    FUTURE ONCOLOGY, 2020, 16 (02) : 4395 - 4408
  • [6] Bosutinib for Chronic Myeloid Leukemia
    Massimo Breccia
    Gianni Binotto
    Rare Cancers and Therapy, 2015, 3 (1-2): : 35 - 46
  • [7] Current Management of Chronic Myeloid Leukemia with Tyrosine Kinase Inhibitors
    Haznedaroglu, Ibrahim C.
    TURKISH JOURNAL OF HEMATOLOGY, 2013, 30 (03) : 247 - 255
  • [8] Profile of bosutinib and its clinical potential in the treatment of chronic myeloid leukemia
    Keller-von Amsberg, Gunhild
    Koschmieder, Steffen
    ONCOTARGETS AND THERAPY, 2013, 6 : 99 - 106
  • [9] Critical review of clinical data and expert-based recommendations for the use of bosutinib in the treatment of chronic myeloid leukemia
    Garcia-Gutierrez, Valentin
    Gomez-Casares, Maria Teresa
    Xicoy, Blanca
    Casado-Montero, Felipe
    Orti, Guillermo
    Giraldo, Pilar
    Hernandez-Boluda, Juan Carlos
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [10] Management of adverse events associated with bosutinib treatment of chronic-phase chronic myeloid leukemia: expert panel review
    Cortes, Jorge E.
    Apperley, Jane F.
    DeAngelo, Daniel J.
    Deininger, Michael W.
    Kota, Vamsi K.
    Rousselot, Philippe
    Gambacorti-Passerini, Carlo
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2018, 11
12345